Sera Prognostics Q4 Non-GAAP EPS Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SERA?
Source: seekingalpha
- Earnings Highlights: Sera Prognostics reported a Q4 Non-GAAP EPS of -$0.16, beating expectations by $0.03, indicating some resilience in profitability despite challenges.
- Revenue Decline: The company's revenue for Q4 was $0.01 million, a 50% year-over-year decrease, reflecting weak market demand and challenges that could impact future cash flow.
- Market Reaction: Despite the significant revenue drop, the better-than-expected Non-GAAP EPS may temporarily boost investor confidence and help stabilize the stock price in the short term.
- Future Outlook: The company needs to implement effective strategies to address the revenue decline challenges to restore growth and enhance market competitiveness, especially in the current economic environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SERA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SERA
Wall Street analysts forecast SERA stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.010
Low
5.00
Averages
5.00
High
5.00
Current: 2.010
Low
5.00
Averages
5.00
High
5.00
About SERA
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sera Prognostics Reports 2025 Financial Results and Strategic Progress
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, a 58.3% decline from $24,000 in Q4 2024, indicating challenges in the commercialization process, while total annual revenue reached $81,000, up 5.2% from $77,000 in 2024, reflecting gradual market acceptance improvements.
- Cost Control: Total operating expenses for Q4 2025 were $9.0 million, down 4.3% from $9.4 million in Q4 2024, with R&D expenses at $3.2 million, slightly higher than last year's $3.1 million, indicating a balance between R&D and market promotion to support future growth.
- Net Loss: The net loss for Q4 2025 was $7.9 million, an 8.2% decrease from $8.6 million in Q4 2024, demonstrating ongoing efforts in capital management despite pressures on revenue expansion.
- Cash Flow and Financing: As of December 31, 2025, the company had approximately $95.8 million in cash and cash equivalents, expected to fund significant market adoption and commercial milestones through 2028, enhancing investor confidence in future growth.
See More
Sera Prognostics Q4 Non-GAAP EPS Beats Expectations
- Earnings Highlights: Sera Prognostics reported a Q4 Non-GAAP EPS of -$0.16, beating expectations by $0.03, indicating some resilience in profitability despite challenges.
- Revenue Decline: The company's revenue for Q4 was $0.01 million, a 50% year-over-year decrease, reflecting weak market demand and challenges that could impact future cash flow.
- Market Reaction: Despite the significant revenue drop, the better-than-expected Non-GAAP EPS may temporarily boost investor confidence and help stabilize the stock price in the short term.
- Future Outlook: The company needs to implement effective strategies to address the revenue decline challenges to restore growth and enhance market competitiveness, especially in the current economic environment.
See More
Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
See More
Sera Prognostics to Present at TD Cowen Health Care Conference
- Conference Participation: Sera Prognostics will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, showcasing the company's latest achievements, which is expected to attract investor attention and enhance the company's market image.
- Innovative Testing: The company's PreTRM® Test is the only broadly validated blood-based biomarker test that predicts the risk of spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling physicians to make more personalized clinical decisions and improve maternal and neonatal health management.
- Preterm Birth Issue: According to the 2025 March of Dimes Report, the U.S. received a D+ grade for preterm birth for the fourth consecutive year, highlighting the long-term challenges in improving preterm birth rates, with healthcare costs associated with prematurity estimated at $25 billion in 2016, imposing a significant economic burden on society.
- Future Outlook: Sera Prognostics' participation not only demonstrates its leadership in maternal and neonatal health but may also enhance the market acceptance of the PreTRM Test, driving future revenue growth and capital management needs.
See More
Sera Prognostics Launches New Blood Test Significantly Reducing Preterm Birth Risk
- Preterm Risk Screening: The PRIME study demonstrates that among 5,018 women, those identified as high-risk through the PreTRM Test and receiving targeted interventions significantly reduced preterm birth risks and improved neonatal outcomes, highlighting the test's effectiveness in early identification of at-risk pregnancies.
- Intervention Effectiveness: By administering daily vaginal progesterone and low-dose aspirin, the study found that women using the PreTRM Test had a significantly lower NICU admission rate compared to standard care, with approximately 39 women needing to be screened to prevent a single NICU admission.
- Strengthening Clinical Evidence: Zhenya Lindgardt, CEO of Sera Prognostics, noted that the findings not only reinforce the strong results from the AVERT PRETERM Trial but also build a robust clinical evidence base for the PreTRM test-and-treat strategy, driving transformation in maternal and neonatal health.
- Future Outlook: Sera Prognostics aims to enhance maternal and neonatal health outcomes through education and equitable access to prenatal care, anticipating measurable value for patients, providers, and health systems while setting a new commercial and clinical standard.
See More
Biotech Stocks Decline, Sera Prognostics Falls 10.1%
- Market Underperformance: Biotechnology stocks collectively declined by approximately 1.1%, indicating the sector's vulnerability in the current market environment, which could negatively impact investor confidence and lead to capital outflows.
- Individual Stock Drag: Sera Prognostics saw a significant drop of about 10.1%, while Rezolute fell approximately 9.1%, raising concerns about the overall biotech sector and potentially affecting the fundraising capabilities of related companies.
- Industry Trends: The overall weakness in the biotech sector may reflect investor caution regarding the progress of new drug developments, particularly amid increasing economic uncertainties, which could lead to reduced investments within the industry.
- Market Sentiment Impact: As biotech stocks decline, market sentiment may further deteriorate, prompting investors to reassess their investment strategies in the sector, which could affect future capital inflows.
See More
Sera Prognostics Reports 2025 Financial Results and Strategic Progress
- Financial Overview: In Q4 2025, Sera Prognostics reported revenue of $10,000, a 58.3% decline from $24,000 in Q4 2024, indicating challenges in the commercialization process, while total annual revenue reached $81,000, up 5.2% from $77,000 in 2024, reflecting gradual market acceptance improvements.
- Cost Control: Total operating expenses for Q4 2025 were $9.0 million, down 4.3% from $9.4 million in Q4 2024, with R&D expenses at $3.2 million, slightly higher than last year's $3.1 million, indicating a balance between R&D and market promotion to support future growth.
- Net Loss: The net loss for Q4 2025 was $7.9 million, an 8.2% decrease from $8.6 million in Q4 2024, demonstrating ongoing efforts in capital management despite pressures on revenue expansion.
- Cash Flow and Financing: As of December 31, 2025, the company had approximately $95.8 million in cash and cash equivalents, expected to fund significant market adoption and commercial milestones through 2028, enhancing investor confidence in future growth.
See More
Sera Prognostics Q4 Non-GAAP EPS Beats Expectations
- Earnings Highlights: Sera Prognostics reported a Q4 Non-GAAP EPS of -$0.16, beating expectations by $0.03, indicating some resilience in profitability despite challenges.
- Revenue Decline: The company's revenue for Q4 was $0.01 million, a 50% year-over-year decrease, reflecting weak market demand and challenges that could impact future cash flow.
- Market Reaction: Despite the significant revenue drop, the better-than-expected Non-GAAP EPS may temporarily boost investor confidence and help stabilize the stock price in the short term.
- Future Outlook: The company needs to implement effective strategies to address the revenue decline challenges to restore growth and enhance market competitiveness, especially in the current economic environment.
See More
Sera Prognostics to Announce Q4 and FY 2025 Financial Results
- Earnings Release Schedule: Sera Prognostics will report its Q4 and FY 2025 financial results on March 18, 2026, after market close, which is expected to positively influence investor confidence.
- Conference Call Details: The company will host a conference call at 5:00 PM ET on the same day to discuss financial results and operational highlights, enhancing transparency and attracting more investor interest.
- Innovative Testing Product: Sera's PreTRM® Test is the only broadly validated blood-based biomarker test that provides early, individualized risk predictions for spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling more informed clinical decisions by physicians.
- Market Demand Context: The 2025 March of Dimes report indicates persistent poor preterm birth rates in the U.S., affecting newborn health, and Sera's products are poised to improve this situation by providing early intervention information, potentially reducing healthcare costs.
See More
Sera Prognostics to Present at TD Cowen Health Care Conference
- Conference Participation: Sera Prognostics will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, in Boston, showcasing the company's latest achievements, which is expected to attract investor attention and enhance the company's market image.
- Innovative Testing: The company's PreTRM® Test is the only broadly validated blood-based biomarker test that predicts the risk of spontaneous preterm birth during weeks 18 to 20 of pregnancy, enabling physicians to make more personalized clinical decisions and improve maternal and neonatal health management.
- Preterm Birth Issue: According to the 2025 March of Dimes Report, the U.S. received a D+ grade for preterm birth for the fourth consecutive year, highlighting the long-term challenges in improving preterm birth rates, with healthcare costs associated with prematurity estimated at $25 billion in 2016, imposing a significant economic burden on society.
- Future Outlook: Sera Prognostics' participation not only demonstrates its leadership in maternal and neonatal health but may also enhance the market acceptance of the PreTRM Test, driving future revenue growth and capital management needs.
See More
Sera Prognostics Launches New Blood Test Significantly Reducing Preterm Birth Risk
- Preterm Risk Screening: The PRIME study demonstrates that among 5,018 women, those identified as high-risk through the PreTRM Test and receiving targeted interventions significantly reduced preterm birth risks and improved neonatal outcomes, highlighting the test's effectiveness in early identification of at-risk pregnancies.
- Intervention Effectiveness: By administering daily vaginal progesterone and low-dose aspirin, the study found that women using the PreTRM Test had a significantly lower NICU admission rate compared to standard care, with approximately 39 women needing to be screened to prevent a single NICU admission.
- Strengthening Clinical Evidence: Zhenya Lindgardt, CEO of Sera Prognostics, noted that the findings not only reinforce the strong results from the AVERT PRETERM Trial but also build a robust clinical evidence base for the PreTRM test-and-treat strategy, driving transformation in maternal and neonatal health.
- Future Outlook: Sera Prognostics aims to enhance maternal and neonatal health outcomes through education and equitable access to prenatal care, anticipating measurable value for patients, providers, and health systems while setting a new commercial and clinical standard.
See More
Biotech Stocks Decline, Sera Prognostics Falls 10.1%
- Market Underperformance: Biotechnology stocks collectively declined by approximately 1.1%, indicating the sector's vulnerability in the current market environment, which could negatively impact investor confidence and lead to capital outflows.
- Individual Stock Drag: Sera Prognostics saw a significant drop of about 10.1%, while Rezolute fell approximately 9.1%, raising concerns about the overall biotech sector and potentially affecting the fundraising capabilities of related companies.
- Industry Trends: The overall weakness in the biotech sector may reflect investor caution regarding the progress of new drug developments, particularly amid increasing economic uncertainties, which could lead to reduced investments within the industry.
- Market Sentiment Impact: As biotech stocks decline, market sentiment may further deteriorate, prompting investors to reassess their investment strategies in the sector, which could affect future capital inflows.
See More
